Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
An Unusual Presentation of Cutaneous Bullous Lupus.
Cureus
November 2024
Rheumatology, Cooper University Health Care, Camden, USA.
Drug-induced lupus erythematosus (DILE) is an autoimmune reaction that results in symptoms of polyarthralgia, fever, and cutaneous lesions and other manifestations. Several drugs have been documented to cause this disease, including procainamide, isoniazid, methyldopa, penicillamine, and hydralazine. Systemic lupus erythematosus (SLE) manifestations often occur after the patient has been taking the drug without complications for months to years.
View Article and Find Full Text PDFDifferent patterns of acute saccadic response to levodopa in de novo Parkinson's disease.
J Neurol
December 2024
Department "G.F. Ingrassia", Section of Neurosciences, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy.
Background: L-dopa (LD) effects on visually guided saccades (VGS) have been poorly investigated in de novo Parkinson's disease (PD) patients through a standardized acute challenge test.
Objectives: To assess the acute saccadic effects of LD as well as possible different patterns of VGS response to LD in a consistent population of de novo PD.
Methods: VGS were assessed among de novo PD at baseline and 2 h after the administration of LD/carbidopa 250/25 mg.
Direct Initiation of Levodopa-Carbidopa Intestinal Gel Infusion After a Positive Levodopa Challenge Test in Advanced Parkinson's Disease.
Brain Behav
December 2024
Department of Neurology, Helsinki University Hospital, Helsinki, Finland.
Introduction: Levodopa-carbidopa intestinal gel (LCIG) is an established treatment option in advanced Parkinson's disease (PD). LCIG treatment is usually initiated with a nasojejunal tube (NJT) test phase before percutaneous endoscopic transgastric jejunostomy (PEG-J) tube installation. However, some centers have used direct initiation with PEG-J.
View Article and Find Full Text PDFDrug-Induced Systemic Lupus Erythematosus: A Rare Presentation of Hydralazine-Induced Lupus.
Cureus
October 2024
Internal Medicine, Arrowhead Regional Medical Center, Colton, USA.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by the production of autoantibodies directed against nuclear and cytoplasmic antigens. SLE can be induced by various medications, such as hydralazine, procainamide, isoniazid, methyldopa, chlorpromazine, quinidine, and minocycline. Hydralazine-induced lupus syndrome was first reported in 1953, and only occurs in 5-10% of patients taking hydralazine.
View Article and Find Full Text PDFAcute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson's Disease.
Neurol Neurochir Pol
December 2024
Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic.
Aim Of Study: To determine whether a high dose of levodopa-carbidopa intestinal gel (LCIG), expressed as levodopa equivalent daily dose (LE daily dose), is a risk factor for acute polyneuropathy in patients treated with LCIG.
Clinical Rationale For Study: Treatment with LCIG is an effective device-assisted therapy in the advanced stages of Parkinson's Disease (PD). Polyneuropathy is a well-known complication of PD treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!